Form 4: Capricor Therapeutics Director George W. Dunbar Jr. Reports Stock Option Grants

Director George W. Dunbar Jr. of Capricor Therapeutics, Inc. reported the acquisition of stock options on January 2, 2025, related to board and committee service.

Summary

• George W. Dunbar Jr., a director at Capricor Therapeutics, Inc., reported the acquisition of stock options on January 2, 2025.
• These options were granted as part of his annual board service and committee service.
• A total of 21,290 stock options were granted at an exercise price of $14.96 per share.
• 11,940 options vest monthly starting February 1, 2025, and ending December 31, 2025.
• 3,600 options are fully vested immediately as of the grant date, related to annual board committee service.
• 5,750 options are also fully vested immediately as of the grant date, related to annual board service.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally positive for aligning interests but not a major market-moving event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule for some options encourages continued service on the board.
• The immediate vesting of some options recognizes the director's contributions to the board and committees.

Risks

• The value of the stock options is dependent on the future performance of Capricor Therapeutics' stock price.
• If the director's service to the company terminates before the vesting of the options, the unvested options may be subject to repurchase by the company.

Industry Context

This is a standard practice for compensating board members and aligning their interests with the company's performance. Stock options are a common form of equity compensation in the biotech industry.

Comparison to Industry Standards

• Stock option grants to board members are a common practice across the biotech industry.
• The vesting schedule of 1/12th per month is a typical vesting schedule for board service.
• The exercise price of $14.96 is specific to Capricor Therapeutics' stock price at the time of the grant.
• Companies like Amgen, Biogen, and Gilead Sciences also use stock options as part of their compensation packages for board members.

Stakeholder Impact

• The stock option grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, Capricor Therapeutics, director, insider trading, SEC Form 4, equity compensation, vesting